Replies to post #194074 on Biotech Values

[DewDiligence]

HRMY acquires ZYNE for $1.1059/sh +CVR—a 226% premium to Friday’s close (excluding the value of the CVR), but a 92% discount to ZYNE’s 2015 IPO (#msg-115948325):

https://www.prnewswire.com/news-releases/harmony-biosciences-to-acquire-zynerba-pharmaceuticals-inc-301899483.html

The nominal deal value (excluding the CVR) is $60M. The CVR is non-tradable.